Primer volumen de la colección Books & Science que reedita en inglés a autores y textos de reconocido prestigio y calidad en sus respectivos campos del conocimiento. Aborda, bajo el prisma de diversas áreas, tanto los problemas psicológicos ocasionados por la ganancia de peso entre los jóvenes, las realidades de su tratamiento, consejos nutricionales, ejercicio físico, educación psicológica… como alternativas y su prevención.

Primer volumen de la colección Books & Science que reedita en inglés a autores y textos de reconocido prestigio y calidad en sus respectivos campos del conocimiento. Aborda, bajo el prisma de diversas áreas, tanto los problemas psicológicos ocasionados por la ganancia de peso entre los jóvenes, las realidades de su tratamiento, consejos nutricionales, ejercicio físico, educación psicológica… como alternativas y su prevención.

These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.

AimLong-acting injectable (LAI) antipsychotics are often used in early psychosis to assist with medication compliance and relapse prevention, although the weight gain and metabolic effects of the newer LAI antipsychotics in young people are yet to be examined. This study examined the long-term effects of aripiprazole and paliperidone in LAI formulation on weight gain and metabolic parameters in youth early episode psychosis.MethodWeight gain and other metabolic effects of the LAI formulations of aripiprazole and paliperidone were examined in 59 youth with early episode psychosis over a 12 month period. Changes in outcome measurements were examined at baseline and 3 monthly intervals.ResultsBoth aripiprazole and paliperidone were associated with time-dependent increases in weight. At 12 months, weight gain increased by an average of 10.1% (7.9 kg) in aripiprazole and 5.3% (4.3 kg) in paliperidone relative to the baseline. Increases in waist size were also significantly greater with aripiprazole (20.8 cm) compared to paliperidone (5.3 cm). Aripiprazole was associated with lower triglycerides and prolactin levels relative to paliperidone.DiscussionBoth LAI medications were associated with substantial weight increases over time. These results build on emerging evidence in young people showing that aripiprazole is not weight neutral. Weight gain is a major concern due to its impact on associated health risks, medication compliance and quality of life, and weight-management programs should be offered from the start of medication initiation.

This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.

Antipsychotic induced weight gain is a growing problem in the United States and globally. There is higher mortality and morbidity rates for individuals with mental health disorders who are taking antipsychotic medications causing significant weight gain. Weight gain results in cardiovascular problems, diabetes, self-esteem problems, and a shorter lifespan. This has a serious impact on the quality of life of individuals with mental health disorders, decreasing social, physical, and sexual functioning. Purpose and background information will be provided concerning antipsychotic induced weight gain. Addressing the problem of antipsychotic-induced weight gain, a lifestyle intervention program over 12-month period with 12 contacts will be implemented and evaluated. In the lifestyle intervention program there will be a focus on an exercise, behavioral education, and diet. The lifestyle intervention program will be evaluated before, 6 months into the program, and after by assessing the weight, waist, BMI, blood pressure, fasting blood sugar levels, total cholesterol, and HDL cholesterol of patients. The outcomes will demonstrate the baseline values and post lifestyle intervention values of the lipid levels, blood pressure levels, glucose levels, and BMI to evaluate the effectiveness of the program to the overall health and weight loss for patients. The findings will be disseminated to key stakeholders.

This volume presents criteria for evaluating treatment programs for obesity and explores what these criteria mean--to health care providers, program designers, researchers, and even overweight people seeking help. Discusses information necessary to make wise program choices and evaluations; examines how client demographics and characteristics--including health status, knowledge of weight-loss issues, and attitude toward weight and body image--affect these programs.

The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management.

Contains highlights of an American College of Neuropsychopharmacology conference on new directions in the development of atypical and other novel antipsychotic drugs. Presents new theories and preclinical and clinical data on various drugs and classes of drugs including amperozide and other drugs.